UPPER MOTOR NEURONE DISEASE · SLOWLY PROGRESSIVE SPASTICITY
A physician-led, laboratory-verified treatment programme targeting upper motor neuron degeneration, corticospinal tract dysfunction and progressive spasticity — tailored to the individual biology, disease stage and clinical profile of each PLS patient.
Request Medical ConsultationAbout the Condition
Primary Lateral Sclerosis (PLS) is a rare neurodegenerative condition affecting the upper motor neurons in the brain and corticospinal tract. Unlike ALS, which involves both upper and lower motor neurons and progresses rapidly, PLS selectively targets upper motor neurons — resulting in gradually increasing spasticity, gait impairment and loss of voluntary motor control over years rather than months.
PLS accounts for approximately 1–3% of all motor neuron disease diagnoses. Onset typically occurs between the ages of 40 and 60. The disease progresses considerably slower than ALS, and life expectancy is often near-normal. However, the progressive spasticity, pseudobulbar affect and loss of mobility significantly reduce quality of life and functional independence.
There is no approved pharmacological treatment that modifies the course of PLS. Standard care relies on symptomatic management of spasticity (baclofen, tizanidine), physiotherapy and assistive devices. Our programme targets the underlying neurodegenerative process — upper motor neuron loss and corticospinal tract deterioration — with the objective of slowing progression and preserving functional capacity.
Classic PLS
The most common presentation. Symmetric, gradually progressive spasticity beginning in the lower limbs and ascending over years to involve the upper limbs, trunk and bulbar musculature. Upper motor neuron signs predominate throughout the disease course. Progression is slow — often measured in years to decades.
Juvenile PLS
An extremely rare hereditary form with onset in childhood or adolescence. Associated with mutations in the ALS2 gene. Presents with progressive spasticity of the limbs and pseudobulbar features. Progression is very slow but onset at a young age results in significant cumulative disability.
PLS with Lower Motor Neurone Features
A subset of patients initially diagnosed with PLS who develop subtle lower motor neuron signs (mild atrophy, fasciculations) after several years. This presentation occupies a clinical boundary between PLS and upper motor neuron–dominant ALS. Close longitudinal monitoring is essential to differentiate the two conditions.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates diagnosis, disease duration, spasticity severity, gait status and overall clinical profile.
We do not offer a cure for PLS. Our programme targets the biological mechanisms driving upper motor neuron degeneration — with the clinical objective of reducing spasticity, preserving mobility and maintaining functional independence for as long as possible.
Clinical Outcomes
The following data are derived from structured observational analysis of PLS patients treated at BioCells Medical between 2015 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
28
PLS patients treated since 2013
74%
measurable functional stabilisation on ALSFRS-R at 3–6 months
+1.2 pts
average ALSFRS-R score change at 6 months — vs. expected −0.5 pts natural decline
71%
sustained functional stability with average 3 years of follow-up
77%
showed improvement in one or more measured domains
73%
retained independence in basic activities of daily living (ADL) at 12 months
Motor & spasticity (lower-limb spasticity reduction, range of motion, walking speed, gait stability)
68%
Bulbar & pseudobulbar (speech clarity, swallowing coordination, pseudobulbar episodes, emotional regulation)
57%
Fine motor (hand coordination, grip strength, object manipulation)
54%
Quality of life (reduced muscle stiffness, daily activity tolerance, fatigue)
71%
3–8 weeks
Initial functional response
3–6 months
Clinically meaningful change
2–3 years onward
Long-term stability — continuous monitoring
Important: Outcomes depend on PLS subtype, baseline spasticity severity, disease duration and individual biological response. Individual results may vary significantly. PLS cohort sizes are smaller than ALS due to the rarity of the condition.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“I walk around the house without the cane now. Most days I make it to the kitchen, the garden, back again. My physiotherapist confirmed the range of motion in both hips improved. First time in years anything moved in the right direction.”
Patient
PLS · Netherlands
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationPatient Cases
Documented treatment outcomes recorded by the BioCells Medical team after personalised regenerative medicine protocols.
The BioCells Program
Our PLS programme combines five biological components into a single personalised protocol. Each is adapted to the specific pathophysiology of upper motor neuron degeneration — targeting corticospinal tract dysfunction, spasticity and pseudobulbar involvement. No two protocols are identical.
Minimally invasive administration
Treatment is delivered by intravenous infusion or targeted local injection using specialised medical systems — not surgical instruments.
No general anaesthesia
Important in PLS, where respiratory function may be compromised in advanced stages and where spasticity-related positioning can complicate anaesthesia management.
No risk of immune rejection
MSCs are immunoprivileged: they express low levels of HLA-I, lack HLA-II and carry a minimal risk of rejection whether the protocol is autologous or allogeneic. Allogeneic MSC protocols do not require immunosuppression.
Targets the underlying biology, not just symptoms
Rather than relying solely on antispasticity medication, our protocol targets upper motor neuron degeneration, corticospinal tract dysfunction and neuroinflammation — the biological drivers of PLS progression.
Complements existing medication
Our programme is compatible with baclofen, tizanidine and other current antispasticity medications. Patients do not need to discontinue existing treatment before commencing our protocol.
Patients from around the world
We work with patients from around the world. Airport transfers, accommodation, visa support and multilingual coordination are included in every treatment programme.
What It Is
MSCs are multipotent regenerative cells with proven immunomodulatory and neuroprotective properties. They are among the most extensively studied cell types in regenerative medicine and have demonstrated safety across thousands of clinical applications worldwide.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 3-5 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are then expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in PLS
In PLS, chronic neuroinflammation within the motor cortex and descending corticospinal pathways drives progressive upper motor neuron loss. MSCs suppress this inflammatory cascade, creating a more stable environment for surviving neurons and supporting the biological conditions needed for functional preservation and spasticity reduction.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, disease stage, spasticity profile, biological markers and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, spasticity severity, gait status, medical history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol based on your Ashworth Scale and Timed 25-Foot Walk assessments.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Airport transfers, accommodation and visa support are included in the programme for international patients.
Structured rehabilitation sessions with our specialist, focused on spasticity management, gait training and functional mobility. Includes targeted stretching, neuromuscular re-education and balance work. Available at our clinic or remotely coordinated with your local medical team.
Your dedicated coordinator monitors spasticity levels, gait performance and overall functional status. A medical-grade wearable bracelet supports continuous health tracking regardless of your location. Clinical reassessment and protocol adjustments are made as your condition evolves.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of PLS patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's clinical status has changed — including significant spasticity exacerbation or respiratory deterioration — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated rehabilitation specialist
monitors spasticity levels, gait performance and overall functional capacity
Personalised rehabilitation programme
focused on spasticity management, range-of-motion maintenance and gait retraining
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in spasticity or mobility
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Biological regeneration in upper motor neuron disease requires sustained monitoring and adjustment over an extended period. The post-treatment phase is as medically important as the treatment itself — particularly in PLS, where the slow disease trajectory means that measurable changes may develop gradually over many months.
Get Started
If you or someone you love has been diagnosed with Primary Lateral Sclerosis, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, current spasticity profile and individual clinical situation.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
